DPYD抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09145(DPYD Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P09145(DPYD Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The DPYD gene encodes dihydropyrimidine dehydrogenase (DPD), a key enzyme responsible for the catabolism of pyrimidine bases and chemotherapeutic agents like 5-fluorouracil (5-FU) and capecitabine. Antibodies targeting DPYD/DPD are primarily used in research and diagnostics to study enzyme expression, assess metabolic deficiencies, or predict patient responses to fluoropyrimidine-based therapies. DPD deficiency, caused by genetic variants in DPYD, affects ~3-5% of the population and is associated with severe toxicity from standard chemotherapy doses.

DPYD antibodies enable the detection of DPD protein levels through techniques like immunohistochemistry (IHC), Western blotting, or ELISA. These tools help identify patients with low DPD activity who may require dose adjustments. Commercially available antibodies are typically raised against specific epitopes of human DPD and validated for various applications. Research using these antibodies has contributed to understanding tissue-specific DPD expression patterns and its role in drug metabolism.

Clinical interest in DPYD antibodies grew alongside pharmacogenomic efforts to personalize chemotherapy. While genetic testing for DPYD variants is standard in some regions, protein-level analysis via antibodies remains complementary, particularly for detecting non-genetic causes of DPD deficiency. Ongoing studies explore correlations between DPD expression, tumor biology, and treatment outcomes.